NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
–Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study,…
Xerox and Lexmark Debut Unified Retail Tech at NRF 2026
PromiCell, Inc. presents during JP Morgan’s 2026 Healthcare Conference